Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study

@article{Ringe2008SustainedEO,
  title={Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study},
  author={Johann Diederich Ringe and Parvis Farahmand and Herbert Faber and Alfred Dorst},
  journal={Rheumatology International},
  year={2008},
  volume={29},
  pages={311-315}
}
The aim of this study was to assess the effect of treatment with risedronate 5 mg daily relative to control in men with primary or secondary osteoporosis over 2 years. Osteoporosis is a common condition in men that can have serious clinical consequences. In an earlier interim report, we found that 1 year of risedronate therapy resulted in significant increases in bone mineral density (BMD) and a significant reduction in vertebral fractures compared to control in men with osteoporosis. We… CONTINUE READING
28 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Risedronate Is e V ective in men with osteoporosis regardless of baseline testosterone level and prevalent vertebral fracture status

  • S Boonen, ES Orwoll, D Wenderoth, KJ Stoner, R Eusebio, PD Delmas
  • JBMR
  • 2006

Risedronate Is eVective in men with osteoporosis regardless of baseline testosterone level and prevalent vertebral fracture status. JBMR 21(Suppl 1):S110

  • S Boonen, ES Orwoll, D Wenderoth, KJ Stoner, R Eusebio, PD Delmas
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…